What the substance is
What is BPC-157?
Before comparing services, separate the name of a substance from a claim that it helps.
A small chain, made in a lab
A peptide is a chain made from the small parts that form proteins.
BPC-157 is a peptide made by chemical synthesis, which means it is put together in a lab. [A]
Researchers designed it to match a small part of a protein they reported finding in the fluid inside the stomach. The BPC-157 discussed here is made in a lab.
The letters stand for Body Protection Compound. A name is a label, not evidence of protection.
Read the healing evidence
Why healing is part of the story
Much of the healing research involves animals, especially rats. [A]
In those studies, researchers reported effects on damaged tendons and other tissues.
That gives a reason to study the substance. An animal result does not establish that the same treatment helps a person.
The human work is small
By September 2026, FDA’s search had identified five human studies; roughly 80 people in total had received BPC-157. [A]
Only two used a comparison group, and neither had a full published paper.
A comparison group receives something else, so researchers can compare what happens. Without one, improvement has more than one possible explanation.
Feeling better does not settle the cause
The small knee-pain and bladder reports had no comparison group, so they cannot show that BPC-157 caused the reported improvement. [A]
Those reports may raise a question for further study. They cannot give the same answer as a careful, completed trial.
A registered study is a plan
As of September 28, 2026, a study in China was enrolling people whose injuries affected the muscles along the back of their thighs. It planned to compare BPC-157 with a treatment containing no active medicine. No results had been posted. [B]
A study listing explains what researchers plan to do. It is not a result.
If a care page calls the substance proven, ask for the completed human study for your specific concern. Ask how it compared with other care.
Page notes
[A] FDA’s BPC-157 briefing: what was studied and what is missing